Ishita Drugs & Industries Ltd.
Snapshot View

44.25 -2.30 ▼-4.9%

30 July 2021, 04:00:00 P.M.
Volume: 1,951

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ishitadrugs.com
Financial Indicators
Market Cap 13.23 Cr.
Earnings per share (EPS) 2.78 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 15.94 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 26.05 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.70 Calculated using Price: 44.25
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.30 Cr. 2,990,300 Shares
FaceValue 10
Company Profile

Ishita drugs & industries limited (IDIL), an Ishita Group company  was incorporated in 1992, the company is listed on the local stock exchanges in India and has earned a reputation as a 'high quality manufacturer' in a very short time.

IDIL is engaged in the manufacture of various active pharma ingredients (bulk actives and their salts), bulk drug intermediates, excipients and fine chemicals. It has a state-of-art manufacturing facility, in terms of chemical synthesis, quality control and environmental safety.

Ishita Group is a respected member of the Indian business community for more than 3 decades. The group's interests encompass manufacture of a large number of bulk actives and their salts, drug intermediates, fine chemicals, food additives, specialty/ performance chemicals, pharmaceutical formulations, healthcare products, dyes and dye intermediates, distribution of financial products and other businesses. The ishita group derives its key strengths from its strong ethical practices and moral values in business commitments.

The company’s manufacturing facility is located on main State Highway 17, barely 25 km from Ahmedabad city. The plant incorporates facilities that are the state-of-art in chemical synthesis, quality control and energy efficiency. The provision of several different utility systems and equipments covering a large number of unit operations make the plant truly multi-purpose. This imparts the flexibility to alter the product mix in tune with the changing market needs or the needs of the customers for customized products.

The plant is equipped with various kinds of equipment to carry out varied kinds of reactions - ss vessels, glass lined ss reactors (glrs), ss centrifuges, rubber lined centrifuges, condensers, fluid bed dryers, ribbon blender, commuting mill, leaf filters, vibrator separators, multi mill etc. The plant also have various utilities suitable for different processes - oil heating, steam heating, ammonia chilling, brine chilling, compressed air, vacuum systems etc.

Product range of the company includes:

The current product list of Ishita includes APIs and intermediates

APIs

Antibiotics

  • Chloramphenicol bp/usp
  • Chloramphenicol palmitate bp/usp

Fluoro quinolones

  • Norfloxacin ip/usp/bp
  • Enrofloxacin base vet

Sulpha drugs

  • Sulfacetamide plain bp/usp
  • Sulphacetamide sodium (drc)
  • Sulfanilamide

Vitamins

  • Nicotinamide usp (inj.) / cosmetics grade
  • Nicotinic acid bp/usp

Anthelmintics

  • Piperazine hydrate
  • Piperazine citrate / adipate / phosphate

Iodides & citrates (salts)

  • Pot.iodide bp
  • Sod.iodide bp
  • Methyl iodide bp
  • Pot.citrate bp/usp
  • Sod.citrate bp/usp
  • Sod.acid citrate bp
  • Sodium chloride bp (pyrogen free)
  • Potassium chloride bp (pyrogen free)

Excipients

  • Maize starch bp
  • Sod.starch glycolate usp
  • Pumojel (sod.starch glycolate)

Other chemicals

  • Methyl nicotinate
  • Pyrazinamide
  • Salicylanilide
  • Para bromo toluene 99.5%
  • Pyridine hydrobromide
  • Potassium phthalimide
  • Nicotinic acid hydrazide

Intermediaries

  • 4-sulfonamido phenyl hydrazine hcl (celecoxib intermediate)
  • 4-chloro phenyl hydrazine hydrochloride
  • Q-acid and n2 ester (norfloxacin intermediates)
  • Tri methyl sulphonoxium iodide
  • 5 cyano phthalide
  • 7-amino - 3 phenyl coumarin
  • 2-hydroxy methyl 3,5 dimethyl 4-methoxy pyridine (omeprazole int.)
  • Hexa methyl disilazane
  • 5-chloromethopabate
  • Diacetyl sulfanilamide
  • L-alanine benzylester p-toluene sulfonate salt
  • 4 (chloroacetyl) n-methyl sulfonamide
  • Indole - 2 - carboxylic acid
  • Ethyl benzoyl acrylate
  • 4, 4' - dimethyl benzil

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.94%
1 Week
-5.45%
1 Month
+62.39%
3 Month
+48.49%
6 Month
+28.82%
1 Year
+173.99%
2 Year
+132.89%
5 Year
+150.0%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 4.57 8.60 3.95 4.12 2.47 3.19 4.17 5.64 8.18
Return on Capital Employed (%) 7.10 12.85 6.27 5.98 4.02 4.79 7.26 8.17 10.79
Return on Assets (%) 3.30 6.23 2.80 3.26 1.81 2.37 3.46 4.54 6.17

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 5 5 5 5 6 6 6 6 7
Non Curr. Liab. 0 0 0 0 0 0 0 0 0
Curr. Liab. 1 3 1 1 3 1 1 2 2
Minority Int.
Equity & Liab. 5 8 7 7 8 7 7 8 9
Non Curr. Assets 1 1 2 1 1 1 1 2 1
Curr. Assets 4 7 5 6 7 6 6 7 8
Misc. Exp. not W/O
Total Assets 5 8 7 7 8 7 7 8 9

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 5 11 7 7 7 6 7 9 15
Other Income 0 0 0 0 0 0 0 0 0
Total Income 5 11 7 7 7 6 7 9 15
Total Expenditure -5 -10 -6 -7 -6 -6 -6 -9 -14
PBIDT 0 1 0 0 0 0 1 1 1
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 0 0 1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 0 1 0 0 1 1 1 1
Cash Fr. Inv. 0 0 0 0 0 -1 -1 -1 -1
Cash Fr. Finan. 0 0 0 0 1 -1 0 0 0
Net Change 0 0 0 0 1 -1 0 0 0
Cash & Cash Eqvt 1 1 1 1 2 1 1 1 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 47.70 47.70 47.70 47.78 47.80 47.87 47.87 47.87 47.87
Public 52.30 52.30 52.30 52.22 52.20 52.13 52.13 52.13 52.13
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 16 Jul 2021
Shareholding for the Period Ended June 30 2021
Ishita Drugs & Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 13 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Srushti Pandya
Designation :- Company Secretary and Compliance Officer
Tue, 13 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
We submit herewith the Confirmation Certificate received from M/S Big share Services Private Limited Registrar and Share Transfer Agent (RTA) as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2021.

Technical Scans View Details

Fri, 30 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%